EMA Authorised: Myocet liposomal (previously Myocet) (doxorubicin hydrochloride) — CHEPLAPHARM Arzneimittel GmbH

View source ↗

Summary

EMA authorised Myocet liposomal (doxorubicin hydrochloride) for breast cancer, with CHEPLAPHARM Arzneimittel GmbH as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Myocet liposomal (doxorubicin hydrochloride liposome)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: CHEPLAPHARM Arzneimittel GmbH. Decision date: 29/05/2024